Phase II DeCOG-Study of Ipilimumab in Pretreated and Treatment-Naïve Patients with Metastatic Uveal Melanoma

PURPOSE: Up to 50% of patients with uveal melanoma (UM) develop metastatic disease with limited treatment options. The immunomodulating agent ipilimumab has shown an overall survival (OS) benefit in patients with cutaneous metastatic melanoma in two phase III trials. As patients with UM were exclude...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:PLoS One
Asıl Yazarlar: Zimmer, Lisa, Vaubel, Julia, Mohr, Peter, Hauschild, Axel, Utikal, Jochen, Simon, Jan, Garbe, Claus, Herbst, Rudolf, Enk, Alexander, Kämpgen, Eckhart, Livingstone, Elisabeth, Bluhm, Leonie, Rompel, Rainer, Griewank, Klaus G., Fluck, Michael, Schilling, Bastian, Schadendorf, Dirk
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Public Library of Science 2015
Konular:
Research Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4356548/
https://ncbi.nlm.nih.gov/pubmed/25761109
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0118564
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller